CARSGEN-B Surges Over 4% in Morning Session Following Recent Collaboration Announcement with Dispatch Bio

Deep News01-22

CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million.

Recently, according to an announcement on the company's official WeChat account, CARSGEN announced a clinical collaboration with Dispatch Bio, a biotechnology firm utilizing its first-in-class Flare platform to develop universal treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026.

This trial will evaluate the combined therapy DISP-11 in patients with solid tumors. The combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, SAIKEZE® (Zevor-cel injection).

SAIKEZE® has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111823522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111823522","market":"hk","top_or_hot":-1,"title":"CARSGEN-B Surges Over 4% in Morning Session Following Recent Collaboration Announcement with Dispatch Bio","media":"Deep News","content":"<p>CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million.</p>\n<p>Recently, according to an announcement on the company's official WeChat account, CARSGEN announced a clinical collaboration with Dispatch Bio, a biotechnology firm utilizing its first-in-class Flare platform to develop universal treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026.</p>\n<p>This trial will evaluate the combined therapy DISP-11 in patients with solid tumors. The combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, SAIKEZE® (Zevor-cel injection).</p>\n<p>SAIKEZE® has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Surges Over 4% in Morning Session Following Recent Collaboration Announcement with Dispatch Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Surges Over 4% in Morning Session Following Recent Collaboration Announcement with Dispatch Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-22 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million.</p>\n<p>Recently, according to an announcement on the company's official WeChat account, CARSGEN announced a clinical collaboration with Dispatch Bio, a biotechnology firm utilizing its first-in-class Flare platform to develop universal treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026.</p>\n<p>This trial will evaluate the combined therapy DISP-11 in patients with solid tumors. The combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, SAIKEZE® (Zevor-cel injection).</p>\n<p>SAIKEZE® has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1111823522","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111823522","pubTimestamp":1769054587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million. Recently, according to an announcement on the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1585":"昨日强势股","BK1161":"生物科技","02171":"科济药业-B","BK1587":"次新股"},"translate_title":"继最近宣布与Dispatch Bio合作后，CARSGEN-B早盘飙升超过4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million.\nRecently, according to an announcement on the company's official WeChat account, CARSGEN announced a clinical collaboration with Dispatch Bio, a biotechnology firm utilizing its first-in-class Flare platform to develop universal treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026.\nThis trial will evaluate the combined therapy DISP-11 in patients with solid tumors. The combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, SAIKEZE® (Zevor-cel injection).\nSAIKEZE® has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111823522","isCrawlerRequest":true}